Review
Accepted on 18 Nov 2024
Enhancing Cancer Therapy: Advanced Nanovehicle Delivery Systems for Oridonin
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1476739
Type at least 3 characters
2,611 articles
Articles
Case Report
Accepted on 18 Nov 2024
Case report: Effective Combination Therapy with Afatinib and Anlotinib in Lung Adenocarcinoma with Uncommon EGFR L858M/L861R Mutations
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1437086
Methods
Published on 18 Nov 2024
Protocol of REACH-01: a single-arm, open label, prospective study of HAIC sequential TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1435639
- 114 views
Original Research
Published on 18 Nov 2024
Maslinic acid induces autophagy and ferroptosis via transcriptomic and metabolomic reprogramming in prostate cancer cells
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1453447
- 204 views
Original Research
Accepted on 15 Nov 2024
Cepharanthine as an effective small cell lung cancer inhibitor: integrated insights from network pharmacology, RNA sequencing, and experimental validation
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1517386
Editorial
Accepted on 15 Nov 2024
Editorial: Genomic Discoveries and Pharmaceutical Development in Urologic Tumors
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1508979
Case Report
Accepted on 15 Nov 2024
Case report: Efficacy of anlotinib and sintilimab in treating lung adenocarcinoma with RET fusion and PD-L1 expression
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1448291
Original Research
Accepted on 14 Nov 2024
Role of Anoikis-related gene RAC3 in prognosis, immune microenvironment, and contribution to malignant behavior in vitro and in vivo of bladder urothelial carcinoma
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1503623
Systematic Review
Accepted on 14 Nov 2024
Interventions for prevention and treatment of trastuzumabinduced cardiotoxicity: an umbrella review of systematic reviews and meta-analyses
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1479983
Original Research
Accepted on 14 Nov 2024
Intratumor microbiome-derived butyrate promotes chemo-resistance in colorectal cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1510851
Correction
Published on 14 Nov 2024
Corrigendum: Myricetin suppresses TGF-β-induced epithelial-to-mesenchymal transition in ovarian cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1447095
- 119 views
Original Research
Published on 13 Nov 2024
Integrated analysis of single-cell and bulk transcriptome reveals hypoxia-induced immunosuppressive microenvironment to predict immunotherapy response in high-grade serous ovarian cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1450751
- 255 views
Review
Published on 13 Nov 2024
Natural products: promising therapeutics for targeting regulatory immune cells in the tumor microenvironment
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1481850
- 239 views
Original Research
Published on 13 Nov 2024
Mechanism of Apigenin against breast cancer stem cells: network pharmacology and experimental validation
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1496664
- 199 views
Review
Published on 13 Nov 2024
Anti-breast cancer effects of dairy protein active peptides, dairy products, and dairy protein-based nanoparticles
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1486264
Original Research
Published on 13 Nov 2024
Magnesium-related gene ITGAL: a key immunotherapy predictor and prognostic biomarker in pan-cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1464830
- 177 views